Gustavo R. Heudebert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gustavo R. Heudebert has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
A. Castiglioni
3 shared publicationsL. L. Willett
3 shared publicationsR. M. Centor
3 shared publicationsR. M. Shewchuk
2 shared publicationsA. H. Salanitro
1 shared publicationC. Mel Wilcox
University of Alabama at Birmingham
1 shared publication
Latest Publications
- 1 January 2007
- Published by BMJ in Journal of Investigative Medicine
- Vol. 55 (1) , S313-S314
HOUSESTAFF VIEWS ON SUCCESSFUL ATTENDING ROUNDS: A MULTI-INSTITUTIONAL STUDY.
- 1 January 2007
- Published by BMJ in Journal of Investigative Medicine
- Vol. 55 (1) , S313-S314
HOUSESTAFF VIEWS ON SUCCESSFUL ATTENDING ROUNDS: A MULTI-INSTITUTIONAL STUDY.
- 1 January 2005
- Published by BMJ in Journal of Investigative Medicine
- Vol. 53 (1) , S314.2-S314
342 WHAT MAKES WARD ATTENDING ROUNDS SUCCESSFUL? A QUALITATIVE STUDY
- 1 January 2005
- Published by BMJ in Journal of Investigative Medicine
- Vol. 53 (1) , S314.2-S314
342 WHAT MAKES WARD ATTENDING ROUNDS SUCCESSFUL? A QUALITATIVE STUDY
- 1 January 2005
- Published by BMJ in Journal of Investigative Medicine
- Vol. 53 (1) , S295.5-S296
242 A PILOT STUDY IMPLEMENTING A PHYSICAL DIAGNOSIS CURRICULUM: DO RESIDENTS BENEFIT FROM TEACHING SESSIONS?
- 1 January 2005
- Published by BMJ in Journal of Investigative Medicine
- Vol. 53 (1) , S295.5-S296
242 A PILOT STUDY IMPLEMENTING A PHYSICAL DIAGNOSIS CURRICULUM: DO RESIDENTS BENEFIT FROM TEACHING SESSIONS?
- 1 March 2000
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 15 (3) , 175-182
What is heartburn worth?
OBJECTIVE: To determine the best treatment strategy for the management of patients presenting with symptoms consistent with uncomplicated heartburn. METHODS: We performed a cost-utility analysis of 4 alternatives: empirical proton pump inhibitor, empirical histamine2-receptor antagonist, and diagnostic strategies consisting of either esophagogastroduodenoscopy (EGD) or an upper gastrointestinal series before treatment. The time horizon of the model was 1 year. The base case analysis assumed a cohort of otherwise healthy 45-year-old individuals in a primary care practice. MAIN RESULTS: Empirical treatment with a proton pump inhibitor was projected to provide the greatest quality-adjusted survival for the cohort. Empirical treatment with a histamine2 receptor antagonist was projected to be the least costly of the alternatives. The marginal cost-effectiveness of using a proton pump inhibitor over a histamine2-receptor antagonist was approximately $10,400 per quality-adjusted life year (QALY) gained in the base case analysis and was less than $50,000 per QALY as long as the utility for heartburn was less than 0.95. Both diagnostic strategies were dominated by proton pump inhibitor alternative. CONCLUSIONS: Empirical treatment seems to be the optimal initial management strategy for patients with heartburn, but the choice between a proton pump inhibitor or histamine2-receptor antagonist depends on the impact of heartburn on quality of life.
- 1 March 2000
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 15 (3) , 175-182
What is heartburn worth?
OBJECTIVE: To determine the best treatment strategy for the management of patients presenting with symptoms consistent with uncomplicated heartburn. METHODS: We performed a cost-utility analysis of 4 alternatives: empirical proton pump inhibitor, empirical histamine2-receptor antagonist, and diagnostic strategies consisting of either esophagogastroduodenoscopy (EGD) or an upper gastrointestinal series before treatment. The time horizon of the model was 1 year. The base case analysis assumed a cohort of otherwise healthy 45-year-old individuals in a primary care practice. MAIN RESULTS: Empirical treatment with a proton pump inhibitor was projected to provide the greatest quality-adjusted survival for the cohort. Empirical treatment with a histamine2 receptor antagonist was projected to be the least costly of the alternatives. The marginal cost-effectiveness of using a proton pump inhibitor over a histamine2-receptor antagonist was approximately $10,400 per quality-adjusted life year (QALY) gained in the base case analysis and was less than $50,000 per QALY as long as the utility for heartburn was less than 0.95. Both diagnostic strategies were dominated by proton pump inhibitor alternative. CONCLUSIONS: Empirical treatment seems to be the optimal initial management strategy for patients with heartburn, but the choice between a proton pump inhibitor or histamine2-receptor antagonist depends on the impact of heartburn on quality of life.